Sharekhan

Sanofi Consumer Healthcare India Ltd

Fri 18/07/2025,15:43:50 NSE: SANOFICONR

₹ 5090.50 -37.00 (-0.72%)
BUY NOW Buy Sanofi Consumer Healthcare India Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Sanofi Consumer Healthcare India Ltd

Fri 18/07/2025,16:1:0

Sanofi Consumer Healthcare India Ltd

Fri 18/07/2025,15:43:50 | NSE : SANOFICONR

₹ 5090.50-37.00 (-0.72%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 5150.00

Previous Close

₹ 5127.50

Volume

1431

Mkt Cap ( Rs. Cr)

₹11723.74

High

₹ 5150.00

Low

₹ 5060.00

52 Week High

₹ 5894.50

52 Week Low

₹ 4211.55

Book Value Per Share

₹ 99.71

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Sanofi Consumer Healthcare India Ltd

Your Vote -

Buy

88.89%

Hold

0.00%

Sell

11.11%

88.89%

9 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

5090.50

20

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

20

Option Chain

Analyzes market sentiment, predicts Sanofi Consumer Healthcare India Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Sanofi Consumer Heal - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    14 Jul 2025, 5:31PM Sanofi Consumer Healthcare India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for

  • Sanofi Consumer Heal - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    14 Jul 2025, 5:24PM Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th June 2025

  • Sanofi Consumer Heal - Trading Window-XBRL

    26 Jun 2025, 5:39PM Sanofi Consumer Healthcare India Limited has informed the Exchange about Closure of Trading Window

  • Sanofi Consumer Heal - Trading Window

    26 Jun 2025, 5:14PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Tradi

  • Sanofi Consumer Heal - Disclosure Under Securities And Exchange Board Of India (Prohibition Of Insider Trading) Regulations,

    13 Jun 2025, 5:32PM Please find enclosed the disclosure received from Opal Bidco SAS, in relation to acquisition of equity shares of the Company pursuant to Open Offer un

  • Sanofi Consumer Heal - Updates

    13 Jun 2025, 5:31PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding disclosure received from Opal Bidco SAS, in relation to acquisition of eq

  • Sanofi Consumer Heal - Copy of Newspaper Publication

    27 May 2025, 11:16AM Citigroup Global Markets India Private Limited has Submitted to the Exchange a copy of post offer advertisement under Regulation 18(12) of?the Securit

  • Sanofi Consumer Heal - Post-Offer Advertisement

    24 May 2025, 8:14AM Citigroup Global Markets India Pvt. Ltd. (\Manager to the Offer\) has submitted to BSE a copy of Post-Offer Advertisement under Regulation 18(12) of

  • Sanofi Consumer Heal - Updates

    12 May 2025, 10:54AM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding 'Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has subm

  • Sanofi Consumer Heal - Updates on Open Offer

    10 May 2025, 3:11PM Citigroup Global Markets India Pvt Ltd (\Manager to the Offer\) has submitted to BSE a copy of disclosure in relation to number of Equity Shares tende

  • Sanofi Consumer Heal - Updates

    9 May 2025, 9:50AM Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Disclosure in relation to number of Equity Sha

  • Sanofi Consumer Heal - Updates on Open Offer

    9 May 2025, 8:28AM Citigroup Global Markets India Pvt Ltd (\Manager to the Offer\) has submitted to BSE a copy of disclosure in relation to number of Equity Shares tende

  • Sanofi Consumer Heal - Updates

    8 May 2025, 10:08AM Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Disclosure in relation to number of Equity Sha

  • Sanofi Consumer Heal - Updates on Open Offer

    8 May 2025, 8:16AM Citigroup Global Markets India Pvt Ltd (\Manager to the Offer\) has submitted to BSE a copy of disclosure in relation to number of Equity Shares tende

  • Sanofi Consumer Heal - Shareholders meeting

    7 May 2025, 4:36PM Sanofi Consumer Healthcare India Limited has submitted the Exchange Voting Results and Consolidated Scrutinizers Report of 2nd Annual General Meeting

  • Sanofi Consumer Heal - Updates

    7 May 2025, 11:01AM Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Disclosure in relation to number of Equity Sha

  • Sanofi Consumer Heal - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    7 May 2025, 4:28PM Please find enclosed Voting Results and Consolidated Scrutinizer's Report of 2nd Annual General Meeting held on 5th May 2025

  • Sanofi Consumer Heal - Updates on Open Offer

    7 May 2025, 8:22AM Citigroup Global Markets India Pvt Ltd (\Manager to the Offer\) has submitted to BSE a copy of disclosure in relation to number of Equity Shares tende

  • Sanofi Consumer Heal - Updates

    6 May 2025, 10:20AM Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Disclosure in relation to number of Equity Sha

  • Sanofi Consumer Heal - Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    7 May 2025, 4:28PM Please find enclosed Voting Results and Consolidated Scrutinizer's Report of 2nd Annual General Meeting held on 5th May 2025

  • Sanofi Consumer Heal - Updates on Open Offer

    6 May 2025, 8:24AM Citigroup Global Markets India Pvt Ltd (\Manager to the Offer\) has submitted to BSE a copy of Disclosure in relation to number of Equity Shares tende

  • Sanofi Consumer Heal - Shareholders meeting

    5 May 2025, 7:20PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on May 05, 2025

  • Sanofi Consumer Heal - Shareholder Meeting / Postal Ballot-Outcome of AGM

    5 May 2025, 7:20PM Please find eclosed a summary of the proceedings of the 2nd Annual General Meeting of the Company held today i.e., 5th May 2025 at 3:30 p.m. (IST)\r\n

  • Sanofi Consumer Heal - Updates

    5 May 2025, 10:23AM Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of addendum to the Letter of Offer and Pre-Offer

  • Sanofi Consumer Heal - Updates

    5 May 2025, 10:12AM Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Disclosure in relation to number of Equity Sha

  • Sanofi Consumer Heal - Copy of Newspaper Publication

    3 May 2025, 10:17PM Sanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Financial Results for the quarter

  • Sanofi Consumer Heal - Updates on Open Offer

    3 May 2025, 10:00AM Citigroup Global Markets India Pvt Ltd (\Manager to the Offer\) has submitted to BSE a copy of addendum to the Letter of Offer and Pre-Offer Advertise

  • Sanofi Consumer Heal - Updates on Open Offer

    3 May 2025, 9:58AM Citigroup Global Markets India Pvt Ltd (\Manager to the Offer\) has submitted to BSE a copy of Disclosure in relation to number of Equity Shares tende

  • Sanofi Consumer Heal - Press Release

    2 May 2025, 9:05PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated May 02, 2025, titled ""Announcement under Regulatio

  • Sanofi Consumer Heal - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    2 May 2025, 9:02PM We wish to inform you that Board of Directors at its meeting today i.e. Friday, 2nd May 2025, inter-alia considered and approved the Unaudited Financi

  • Sanofi Consumer Heal - Board Meeting Outcome For Consideration And Approval Of Unaudited Financial Results For The Quarter En

    2 May 2025, 8:13PM Board Meeting Outcome for consideration and approval of Unaudited Financial Results for the Quarter ended 31st March 2025

  • Sanofi Consumer Heal - Outcome of Board Meeting

    2 May 2025, 7:48PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Outcome of Board Meeting held on 2nd May 2025 to consider and approve the

  • Sanofi Consumer Heal Q1 net profit down 20.26% at Rs 50.00 cr

    2 May 2025, 7:40PM The company reported standalone net profit of Rs 50.00 crore for the quarter ended March 31, 2025 as compared to Rs 62.70 crore in the same period las

  • Sanofi Consumer Heal - Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, 2Nd May 2025

    2 May 2025, 7:34PM We refer to our letter dated 25th April 2025 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that t

  • Sanofi Consumer Heal - Updates

    2 May 2025, 10:32AM Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Disclosure in relation to number of Equity Sha

  • Sanofi Consumer Heal - Updates on Open Offer

    2 May 2025, 8:56AM Citigroup Global Markets India Pvt Ltd (\Manager to the Offer\) has submitted to BSE a copy of Disclosure in relation to number of Equity Shares tende

  • Sanofi Consumer Heal - Press Release

    1 May 2025, 7:43PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated April 30, 2025, titled ""Sanofi and CD&R close Opel

  • Sanofi Consumer Heal - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    1 May 2025, 7:32PM Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

  • Sanofi Consumer Heal - Updates

    30 Apr 2025, 10:57AM Citigroup Global Markets India Pvt. Ltd. (Manager to the Offer) has submitted to the Exchange a copy of Disclosure in relation to number of Equity Sha

  • Sanofi Consumer Heal - Updates on Open Offer

    30 Apr 2025, 8:35AM Citigroup Global Markets India Pvt. Ltd. (\Manager to the Offer\) has submitted to BSE a copy of Disclosure in relation to number of Equity Shares ten

  • Sanofi Consumer Heal - Trading Window-XBRL

    29 Apr 2025, 6:23PM Sanofi Consumer Healthcare India Limited has informed the Exchange about Closure of Trading Window

  • Sanofi Consumer Heal - Board Meeting Intimation

    26 Apr 2025, 2:40PM Sanofi Consumer Healthcare India Limited has informed the Exchange about Board Meeting to be held on 02-May-2025 to inter-alia consider and approve th

  • Sanofi Consumer Heal - Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Fina

    25 Apr 2025, 7:52PM Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2025 ,inter alia,

  • Sanofi Consumer Heal - Updates

    24 Apr 2025, 6:34PM Citigroup Global Markets India Private Ltd has submitted to the Exchange a copy Pre-offer Advertisement in accordance with Regulation 18(7) and other

  • Sanofi Consumer Heal - Updates on Open Offer

    24 Apr 2025, 5:46PM Citigroup Global Markets India Pvt. Ltd. (\Manager to the Offer\) has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulatio

  • Sanofi Consumer Heal - Corrigendum

    23 Apr 2025, 7:26PM Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Corrigendum to the Annual Report for Financial Year 2024

  • Sanofi Consumer Heal - Corrigendum To The Annual Report For Financial Year 2024

    23 Apr 2025, 7:25PM Corrigendum to the Annual Report for Financial Year 2024

  • Sanofi Consumer Heal - Reg. 34 (1) Annual Report.

    23 Apr 2025, 5:57PM Corrigendum to the Annual Report for Financial Year 2024 due to inadvertent typographical errors in the disclosed figures on page no.53 under the sect

  • Sanofi Consumer Heal has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    21 Apr 2025, 8:00PM As of March 2025, 60.40% is owned by Foreign Promoters and 39.60% by Public. <p align=justify> Institutional holds 30.00% (Insurance Companies 9.78%)
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Sanofi Consumer Healthcare India Ltd stock 

Name December-24 March-24 December-23
Assets 1.7 1.7 1.7
Liabilities 1.7 1.7 1.7
Equity 2 2 2
Gross Profit 0 0 -0.3
Net Profit 0 0 -0.3
Cash From Operating Activities -0.4 -0.4 -0.4
NPM(%) 0 0 29.69
Revenue 0 0 0
Expenses 0 0 0.3
ROE(%) 0 0 -0.13

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
17 Apr 2025 55 550 0 4756.85

Peers

Other companies within the same industry or sector that are comparable to Sanofi Consumer Healthcare India Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Sharda Cropchem Ltd 839.75 5.09 24.89 45908.70 337.37 1.07
Amines and Plasticizers Ltd 240.71 -3.31 32.31 27996.93 372.61 0.21
Indogulf Cropsciences Ltd 113.34 -2.13 0.00 11967.49 44.66 0.00
Grauer and Weil (India) Ltd 115.60 0.00 33.31 115359.35 346.66 0.43

Company Info

The Company was incorporated as a public limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated May 10, 2023, issued by the Registrar of Companies, Central Registration Centre. Major Events and Milestones:2023 Incorporation of the Company 2024 Demerger, transfer and vesting of the Demerged Undertaking from Sanofi India Limited into the  Company on a going concern basis pursuant to the Scheme  2020 -Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030. 2021 -Sanofi completed acquisition of Kadmon. -Sanofi completed acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics. -Sanofi launched its new global employee share ownership plan. -Sanofi established three-year collaboration with Stanford Medicine to accelerate immunology research. 2022 -Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology. -Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine. -Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth. -Sanofi recognized by S&P as one of the most sustainability- committed companies. -Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board. 2023 -Sanofi's Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability. -Sanofi completes acquisition of Qunol. -Sanofi completes acquisition of Provention Bio, Inc. - Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care. 2024 -Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline.

The Company was incorporated as a public limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated May 10, 2023, issued by the Registrar of Companies, Central Registration Centre. Major Events and Milestones:2023 Incorporation of the Company 2024 Demerger, transfer and vesting of the Demerged Undertaking from Sanofi India Limited into the  Company on a going concern basis pursuant to the Scheme  2020 -Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030. 2021 -Sanofi completed acquisition of Kadmon. -Sanofi completed acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics. -Sanofi launched its new global employee share ownership plan. -Sanofi established three-year collaboration with Stanford Medicine to accelerate immunology research. 2022 -Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology. -Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine. -Sanofi launches its first Digital Accelerator fueled by new talent and focused on growth. -Sanofi recognized by S&P as one of the most sustainability- committed companies. -Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board. 2023 -Sanofi's Consumer Healthcare Unit launches the Shared Care Collective, an advisory group working to advance sustainability. -Sanofi completes acquisition of Qunol. -Sanofi completes acquisition of Provention Bio, Inc. - Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care. 2024 -Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline.

Read More

Parent Organisation

Sanofi Consumer Healthcare India Ltd.

Founded

10/05/2023

Managing Director

Mr.Himanshu Bakshi

NSE Symbol

SANOFICONREQ

FAQ

The current price of Sanofi Consumer Healthcare India Ltd is ₹ 5090.50.

The 52-week high for Sanofi Consumer Healthcare India Ltd is ₹ 5150.00 and the 52-week low is ₹ 5060.00.

The market capitalization of Sanofi Consumer Healthcare India Ltd is currently ₹ 11723.74. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Sanofi Consumer Healthcare India Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Sanofi Consumer Healthcare India Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Sanofi Consumer Healthcare India Ltd shares.

The CEO of Sanofi Consumer Healthcare India Ltd is Mr.Himanshu Bakshi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT